Article
European Journal of Human Genetics (2009) 17, 946–957; doi:10.1038/ejhg.2008.264; published online 21 January 2009
Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis
Anna C Need1, Richard SE Keefe2, Dongliang Ge1, Iris Grossman1,5, Sam Dickson1,3, Joseph P McEvoy2,4 and David B Goldstein1
- 1Center for Human Genome Variation, Institute for Genome Sciences & Policy, Duke University, Durham, NC 27708, USA
- 2Department of Psychiatry, Duke University Medical Center, Durham, NC, USA
- 3Bioinformatics Research Center, North Carolina State University, Raleigh, NC, USA
- 4Biological Psychiatry, John Umstead Hospital, Butner, NC, USA
Correspondence: Dr DB Goldstein, Center for Human Genome Variation, Institute for Genome Sciences & Policy, Duke University, Durham, NC 27708, USA. Tel: +1 919 684 0896; Fax: +1 919 668 6787; E-mail: d.goldstein@duke.edu
5Current address: Pharmacogenetics Consultancy, Cabernet Pharmaceuticals, R. David Thomas Center, One Science Drive, Box 90344, Durham, NC 27708, USA
Received 11 June 2008; Revised 11 October 2008; Accepted 9 December 2008; Published online 21 January 2009.
Abstract
The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Phase 1 Schizophrenia trial compared the effectiveness of one typical and four atypical antipsychotic medications. Although trials such as CATIE present important opportunities for pharmacogenetics research, the very richness of the clinical data presents challenges for statistical interpretation, and in particular the risk that data mining will lead to false-positive discoveries. For this reason, it is both misleading and unhelpful to perpetuate the current practice of reporting association results for these trials one gene at a time, ignoring the fact that multiple gene-by-phenotype tests are being carried out on the same data set. On the other hand, suggestive associations in such trials may lead to new hypotheses that can be tested through both replication efforts and biological experimentation. The appropriate handling of these forms of data therefore requires dissemination of association statistics without undue emphasis on select findings. Here we attempt to illustrate this approach by presenting association statistics for 2769 polymorphisms in 118 candidate genes evaluated for 21 pharmacogenetic phenotypes. On current evidence it is impossible to know which of these associations may be real, although in total they form a valuable resource that is immediately available to the scientific community.
Keywords:
schizophrenia, neurocognition, RIMS1, quetiapine, GRM8, discontinuation
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
RESEARCH
Baseline Neurocognitive Deficits in the CATIE Schizophrenia Trial
Neuropsychopharmacology Original Article
Neuropsychopharmacology Original Article
Neuropsychopharmacology Original Article
A Placebo-Controlled Add-On Trial of the Ampakine, CX516, for Cognitive Deficits in Schizophrenia
Neuropsychopharmacology Original Article

